Published online Aug 7, 2014. doi: 10.3748/wjg.v20.i29.10144
Revised: February 11, 2014
Accepted: February 17, 2014
Published online: August 7, 2014
Processing time: 327 Days and 13.6 Hours
AIM: To provide trends in incidence, management and survival of cancer of the ampulla of Vater in a well-defined French population.
METHODS: Data were obtained from the population-based digestive cancer registry of Burgundy over a 34-year period. Age-standardized incidence rates were computed using the world standard population. Average annual variations in incidence rates were estimated using a poisson regression. A univariate and multivariate relative survival analysis was performed.
RESULTS: Age-standardized incidence rates were 0.46 and 0.30 per 100000 inhabitants for men and women, respectively. Incidence rate increased from 0.26 (1976-1984) to 0.58 (2003-2009) for men and remained stable for women. Resection for cure was performed in 48.3% of cases. This proportion was stable over the study period. Among cases with curative resection, pancreatico-duodenectomy was performed in 94.0% of cases and ampullectomy in 6.0% of cases. A total of 50.8% of cancers of the ampulla of Vater were diagnosed at an advanced stage. Their proportion remained stable throughout the study period. The overall 1- and 5-year relative survival rates were 60.2% and 27.7%, respectively. Relative survival did not vary over time. Treatment and stage at diagnosis were the most important determinants of survival. The 5-year relative survival rate was 41.5% after resection for cure, 9.5% after palliative surgery and 6.7% after symptomatic treatment. In multivariate analysis, only stage at diagnosis significantly influenced the risk of death.
CONCLUSION: Cancer of the ampulla of Vater is still uncommon, but its incidence increased for men in Burgundy. Diagnosis is often made at an advanced stage, dramatically worsening the prognosis.
Core tip: Cancer of the ampulla of Vater is still uncommon, but its incidence increased for men in Burgundy. Cancers were diagnosed at an advanced stage (distant metastasis and/or unresectable) in 50.8% of the cases. Resection for cure was performed in half of patients. The absence of improvement in stage at diagnosis and overall survival over time is disappointing. The overall 5-year relative survival rate was 27.7%, and did not vary over time. The 5-year relative survival rate was 41.5% after resection for cure, 9.5% after palliative surgery and 6.7% after symptomatic treatment. In multivariate analysis, only stage at diagnosis significantly influenced the risk of death.